Literature DB >> 2816647

MR findings in methotrexate-induced CNS abnormalities.

F Ebner1, G Ranner, I Slavc, C Urban, R Kleinert, H Radner, R Einspieler, E Justich.   

Abstract

MR of the brain was performed in eight patients (mean age, 14.9 years) with osteogenic sarcoma during or after IV treatment with high-dose methotrexate. MR detected brain abnormalities in four patients, three of whom had concomitant neurologic dysfunction. Pathologic findings demonstrated on MR were (1) chronic brain edema, demonstrable over a period of 3-14 months (proved by autopsy in one patient); (2) multifocal white matter necrosis; and (3) deep brain atrophy. MR appears to be valuable in the detection of abnormalities induced by treatment with high-dose methotrexate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2816647     DOI: 10.2214/ajr.153.6.1283

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

1.  Evaluation of treatment-induced cerebral white matter injury by using diffusion-tensor MR imaging: initial experience.

Authors:  Sawako Kitahara; Satoshi Nakasu; Kiyoshi Murata; Keizen Sho; Ryuta Ito
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

2.  Mineralizing microangiopathy: CT and MRI.

Authors:  D J Shanley
Journal:  Neuroradiology       Date:  1995-05       Impact factor: 2.804

3.  Carmofur-induced leukoencephalopathy: MRI.

Authors:  S Matsumoto; S Nishizawa; M Murakami; S Noma; A Sano; Y Kuroda
Journal:  Neuroradiology       Date:  1995-11       Impact factor: 2.804

4.  The effect of corticosteroid medication on quantitative MR parameters of the brain.

Authors:  Stefan C A Steens; Gerda M Steup-Beekman; Gerlof P Th Bosma; Faiza Admiraal-Behloul; Hans Olofsen; Joost Doornbos; Tom W J Huizinga; Mark A van Buchem
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

5.  Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.

Authors:  April F Eichler; Tracy T Batchelor; John W Henson
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.